MedTrace Logo

INVISION - An Observational Study to Explore Effectiveness, Tolerability and Safety of Paliperidone ER in Patients With Schizophrenia

NCT00697658 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 27

Last updated 2014-04-28

No results posted yet for this study

Summary

The purpose of this study is to explore efficacy, tolerability and safety of paliperidone Extended Release (ER) in 250 schizophrenia patients who started treatment with paliperidone ER in a naturalistic setting.

Conditions

Interventions

DRUG

Paliperidone ER

6 mg tablet once daily, variable treatment length.

Sponsors & Collaborators

  • Janssen-Cilag B.V.

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag B.V. Clinical Trial · Janssen-Cilag B.V.

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00697658 on ClinicalTrials.gov